
Federal contracting giant Leidos is responding to federal grand jury subpoenas issued as part of two separate Department of Justice investigations, according to company filings.
The publicly listed company received a request for documents in August relating to a criminal investigation by the DOJ’s antitrust division, as well as a request for documents arising from a probe launched by the department’s fraud division.
Leidos disclosed details of the investigations in its third quarter results, but said it could not offer further guidance on investigation timings or likely outcomes.
Related: Adobe-Figma Deal Faces DOJ Antitrust Probe
According to Leidos, the DOJ’s antitrust division in August requested documents relating to three government procurements associated with the company’s intelligence group in 2021 and 2022.
“We intend to fully cooperate with the investigation, and we are conducting our own internal investigation with the assistance of outside counsel,” the company said in filings.
In September, the DOJ’s fraud division sought documents from the company relating to a second investigation. Leidos noted that this was launched after the company self-reported unspecified conduct that may have violated laws including the Foreign Corrupt Practices Act.
Leidos is one of the largest providers of technology to federal agencies such as the Department of Defense, Department of Homeland Security and NASA.
The company reported revenues of $1.8 billion from DOD and Intelligence Community work during the third quarter of 2022 and revenues of $1.3 billion from contracts with other civilian government agencies.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas